Successful intranasal（鼻内的） delivery of stem cells to the brains of rats with Parkinson disease yielded significant improvement in motor function and reversed the dopamine（多巴胺） deficiency characteristic of the disease. These highly promising¹ findings, reported in Rejuvenation² Research, a peer-reviewed journal published by Mary Ann Liebert, Inc. highlight the potential for a noninvasive approach to cell therapy delivery in Parkinson disease–a safer and effective alternative to surgical³ transplantation of stem cells. The article is available free online. In this groundbreaking study, mesenchymal（间叶细胞的） stem cells (MSCs) delivered via the nose preferentially migrated to the brain and were able to survive for at least 6 months. Substantial improvement in motor function—up to 68% of normal—was reported in the MSC-treated rat model of Parkinson disease. Levels of the neurotransmitter dopamine were significantly higher in affected⁴ rat brain regions exposed to MSCs compared to the non-treated brain regions, reported Lusine Danielyan and an international team of researchers from University Hospital of Tübingen, University of Göttingen Medical School, and University of Tübingen (Stuttgart, Germany; HealthPartners Research Foundation, St. Paul, MN; German University in Cairo, Egypt; Harvard University, Cambridge, MA; Institute of Molecular⁵ Biology NAS RA, Yerevan, Armenia; and Geneva University Hospital, Switzerland.

The authors present their findings in the article, "Therapeutic⁶ Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease." They explain that intranasal delivery of MSCs avoids the tissue trauma⁷ and related inflammation and brain swelling⁸ associated with surgical implantation of therapeutic stem cells. Importantly, this noninvasive delivery method would also make it possible to provide repeated stem cell treatments over time.